Special Issue "Metal-Based Anticancer Drugs"
Deadline for manuscript submissions: 30 June 2022.
Interests: coordination and bioinorganic chemistry, more specifically development of metal-based anticancer drugs based on isomeric indoloquinolines, indolobenzazepines, indolobenzazocines and indolobenzazonines, as well as on thiosemicarbazones; ruthenium-nitrosyl complexes with heterocyclic azoles as NO-releasing molecules and potential aniticancer drugs; bis-(thio)semicarbazide macrocyclic complexes as catalysts in alkane oxidation; transition metal complexes with noninnocent open-chain ligands
Interests: vanadium; metals in medicine; drugs and biologically active compounds; lipid and lipid model interfaces; pharmaceutically active compounds; cancer; diabetes; tuberculosis; hydrophobic compounds; spectroscopy; hydrophobic compounds; transition metals; reverse micelles; chemistry in confined spaces
Special Issues, Collections and Topics in MDPI journals
Interests: metal-based drugs; anticancer compounds; antimicrobial compounds; medicinal inorganic chemistry; copper, ruthenium, vanadium and platinum complexes; nanoparticles; drug delivery
The use of metal complexes as anticancer agents revolutionized cancer treatment more than fifty years ago with the discovery of cisplatin, cis-[PtCl2(NH3)2]. Further research led to clinical use of other platinum drugs, namely, carboplatin and oxaliplatin. The main deficiencies of the platinum-based drugs are their severe side effects and drug resistance. New metal-based anticancer drugs including essential and nonessential metals that have a different mode of action might be able to broaden the spectrum of treatable cancers, reduce toxic side effects, and overcome platinum resistance. The concept of selective targeting of cancer cells remains a challenge. Many new approaches to the design of innovative metal-based anticancer drugs are currently emerging. These include prodrugs, dual or multi-action prodrugs, etc. Even though the chemistry of metal-based drugs has made considerable progress, there are other drawbacks such as poor aqueous solubility and pharmacological issues. To enhance the efficacy of new metal-based drugs, prodrug and targeting strategies, as well as suitable drug delivery approaches, are being developed (design and synthesis of new ligands, nanocarriers, etc.). The importance of studies into the underlying mechanisms of action, which have led to new molecular targets for metal-based drugs, is also increasing. This Special Issue aims to highlight the progress in the field of development of new metal-based anticancer drugs.
Prof. Dr. Vladimir Arion
Prof. Dr. Debbie C. Crans
Prof. Dr. Ignacio E. Leon
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Inorganics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- anticancer metallodrugs
- antimicrobial compounds
- drug delivery
- drugs and biologically active compounds
- pharmaceutically active compounds
- metals in medicine